⚕ GalenOps CRO console
← SITE003 (CAN)

SITE003-0249

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2022-12-17
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 22); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-02-03 (study day 39); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-06-15 (study day 171); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-21 (study day 177); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-07-15 (study day 201); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-07 (study day 285); relationship: N

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-04 (study day 313); relationship: Y

mild assessed 2026-08-18

Grade 1 Nausea — outcome: UNKNOWN; onset 2024-01-19 (study day 389); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-05-18 (study day 509); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.